Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP-O2 trial.
Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP-O2 trial.
复制标题
DOI：
10.1111/dom.14537
复制
发表时间：
2021-12
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
为了比较iGlarLixi的益处，iGlarLixi是一种固定比例的甘精胰岛素100 U/mL和利昔那肽（iGlarLixi）与甘精胰岛素（iGlar）的组合，用于降低口服降糖药控制不足的日本2型糖尿病（T2D）患者的残留高血糖（定义为空腹血糖[FPG] < 130 mg/dL，但HbA1c≥7%）。开放标签LixiLan JP - O2研究比较了iGlarLixi和iGlar在521例T2D患者26周内的疗效。该事后分析评估了总体人群中剩余高血糖参与者的比例，以及按年龄和筛查时使用二肽基肽酶- 4抑制剂（DPP4i）定义的亚组。在26周时，iGlarLixi组与iGlar组相比，出现残余高血糖的受试者显著减少（8.1% vs. 19.6%; P = 0.0002）。在所有亚组分析中，iGlarLixi的残余高血糖也少于iGlar: 65岁以下参与者的9.0%对16.8% (P = 0.0369)；65岁及以上受试者为6.5% vs 24.2% (P = 0.0008)；使用DPP4i的受试者为10.1%对20.5% (P = 0.0202)；未使用DPP4i组为6.2%，未使用DPP4i组为18.8% （P = 0.0024）。总体人群中，iGlarLixi组HbA1c低于7%、FPG低于130 mg/dL的比例高于iGlar组（50.8% vs. 31.5%; P < 0.05）。0001)，并且在所有的研究亚组中。与iGlar相比，iGlarLixi降低了未控制T2D的日本人的残余高血糖患病率，无论是在总体人群中，还是在按年龄和筛查时使用DPP4i定义的亚组中。
To compare the benefits of iGlarLixi, a fixed‐ratio combination of insulin glargine 100 U/mL and lixisenatide (iGlarLixi), with insulin glargine (iGlar) for reducing residual hyperglycaemia (defined as HbA1c ≥ 7% despite fasting plasma glucose [FPG] < 130 mg/dL) in Japanese people with type 2 diabetes (T2D) inadequately controlled on oral antidiabetic drugs. The open‐label LixiLan JP‐O2 study compared iGlarLixi with iGlar over 26 weeks in 521 people with T2D. This post hoc analysis assessed the proportions of participants with residual hyperglycaemia in the overall population, and in subgroups defined by age and dipeptidyl peptidase‐4 inhibitor (DPP4i) use at screening. At 26 weeks, significantly fewer participants had residual hyperglycaemia in the iGlarLixi versus the iGlar arm (8.1% vs. 19.6%; P = .0002). There was also less residual hyperglycaemia with iGlarLixi than iGlar in all subgroup analyses: 9.0% versus 16.8% in participants aged younger than 65 years (P = .0369); 6.5% versus 24.2% in participants aged 65 years or older (P = .0008); 10.1% versus 20.5% (P = .0202) in participants with DPP4i use; and 6.2% versus 18.8% in those without DPP4i use (P = .0024). The proportion reaching both HbA1c less than 7% and FPG less than 130 mg/dL was higher with iGlarLixi versus iGlar in the overall population (50.8% vs. 31.5%; P < .0001), and in all studied subgroups. iGlarLixi reduced the prevalence of residual hyperglycaemia in Japanese people with uncontrolled T2D compared with iGlar, both in the overall population and in subgroups defined by age and DPP4i use at screening.
登录
查看更多内容
影响因子：
13.1
作者：
Wilkinson DJ;Piasecki M;Atherton PJ
通讯作者：
Atherton PJ
DOI：
10.1007/s13300-018-0395-3
发表时间：
2018-06
期刊：
Diabetes therapy : research, treatment and education of diabetes and related disorders
影响因子：
--
作者：
Meece J
通讯作者：
Meece J
影响因子：
5.8
作者：
Kaneto, Hideaki;Takami, Akane;Niemoeller, Elisabeth
通讯作者：
Niemoeller, Elisabeth
影响因子：
5.8
作者：
Terauchi, Yasuo;Nakama, Takahiro;Niemoeller, Elisabeth
通讯作者：
Niemoeller, Elisabeth
影响因子：
2.9
作者：
Nishimura, Rimei;Kato, Haruka;Shimasaki, Yukio
通讯作者：
Shimasaki, Yukio